Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

Core Viewpoint - Longeveron Inc. is set to report its 2025 full year financial results and provide a business update on March 17, 2026, after U.S. financial markets close, followed by a conference call and webcast [1]. Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to meet unmet medical needs [3]. - The company's lead investigational product is laromestrocel (LOMECEL-B), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [3]. - Laromestrocel has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [3]. - The company is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (PDCM), and Aging-related Frailty [3]. - Laromestrocel has received five important FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for the HLHS program; and Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the AD program [3].